Antibodies Assay Kits Bap1 Antibody Biology Cells Brd4 Antibody Canine Albumin cDNA Culture Cells Devices Glut2 Antibody Gsk3 Alpha Hama Antibodies Medium & Serums Muc2 Antibody NATtrol Nedd4 Antibody Nox1 Antibody PCR Reagents Recombinant Proteins Ria Kits RNA Tgf Alpha Elisa Vector & Virus Vi Alpha Vitronectin Antibody Western Blot Zebrafish Antibodies
Human-SARS-CoV-2 interactome and human genetic diversity: TMPRSS2-rs2070788, associated with severe influenza, and its population genetics caveats in Native Americans
For human/SARS-CoV-2 interactome genes ACE2, TMPRSS2 and BSG, there’s a convincing proof of affiliation in Asians with influenza-induced SARS for TMPRSS2-rs2070788, tag-SNP of the eQTL rs383510. This case illustrates the significance of inhabitants genetics and of sequencing knowledge within the design of genetic affiliation research in several human populations: the excessive linkage disequilibrium (LD) between rs2070788 and rs383510 is Asian-specific.
Leveraging on a mixture of genotyping and sequencing knowledge for Native Individuals (uncared for in genetic research), we present that whereas their frequencies of the Asian tag-SNP rs2070788 is, surprisingly, the best worldwide, it isn’t in LD with the eQTL rs383510, that subsequently, must be straight genotyped in genetic affiliation research of SARS in populations with Native American ancestry.
PRICKLE1 × FOCAD Interplay Revealed by Genome-Broad vQTL Evaluation of Human Facial Traits
The human face is a extremely advanced and variable construction ensuing from the intricate coordination of quite a few genetic and non-genetic elements. A whole bunch of genomic loci impacting quantitative facial options have been recognized.
Whereas these associations have been proven to affect morphology by altering the imply dimension and form of facial measures, their impact on trait variance stays unclear. We carried out a genome-wide affiliation evaluation for the variance of 20 quantitative facial measurements in 2,447 European people and recognized a number of suggestive variance quantitative trait loci (vQTLs).
These vQTLs guided us to conduct an environment friendly seek for gene-by-gene (G × G) interactions, which uncovered an interplay between PRICKLE1 and FOCAD affecting cranial base width. We replicated this G × G interplay sign on the locus stage in an extra 5,128 Korean people.
We used the hypomorphic Prickle1 Beetlejuice (Prickle1 Bj ) mouse line to straight take a look at the perform of Prickle1 on the cranial base and noticed wider cranial bases in Prickle1 Bj/Bj . Importantly, we noticed that the Prickle1 and Focadhesin proteins co-localize in murine cranial base chondrocytes, and this co-localization is irregular within the Prickle1 Bj/Bj mutants.
Taken collectively, our findings uncovered a novel G × G interplay impact in people with robust help from each epidemiological and molecular research. These outcomes spotlight the potential of finding out measures of phenotypic variability in gene mapping research of facial morphology.
Proof for opposing selective forces working on human-specific duplicated TCAF genes in Neanderthals and people
TRP channel-associated issue half (TCAF1/TCAF2) proteins antagonistically regulate the cold-sensor protein TRPM8 in a number of human tissues. Understanding their significance has been difficult given the locus spans a gap-ridden area with advanced segmental duplications in GRCh38. Utilizing long-read sequencing, we sequence-resolve the locus, annotate full-length TCAF fashions in primate genomes, and present substantial human-specific TCAF copy quantity variation.
We determine two human tremendous haplogroups, H4 and H5, and set up that TCAF duplications originated ~1.7 million years in the past however diversified solely in Homo sapiens by recurrent structural mutations. Conversely, in all archaic-hominin samples the fixation for a particular H4 haplotype with out duplication is probably going on account of constructive choice.
Right here, our outcomes of TCAF copy quantity enlargement, choice alerts in hominins, and differential TCAF2 expression between haplogroups and excessive TCAF2 and TRPM8 expression in liver and prostate in modern-day people suggest TCAF diversification amongst hominins doubtlessly in response to chilly or dietary diversifications.
A world map of associations between varieties of protein posttranslational modifications and human genetic ailments
There are >200 varieties of protein posttranslational modifications (PTMs) described in eukaryotes, every with distinctive proteome protection and capabilities. We hypothesized that some genetic ailments could also be attributable to the removing of a particular kind of PTMs by genomic variants and the resultant deregulation of explicit capabilities.
We collected >320,000 human PTMs representing 59 varieties and crossed them with >4M nonsynonymous DNA variants annotated with predicted pathogenicity and illness associations. We report >1.74M PTM-variant co-occurrences that an enrichment evaluation distributed into 215 pairwise associations between 18 PTM varieties and 148 genetic ailments.
Of them, 42% weren’t beforehand described. Elimination of lysine acetylation exerts probably the most pronounced impact, and fewer studied PTM varieties equivalent to S-glutathionylation or S-nitrosylation present relevance. Utilizing pathogenicity predictions, we recognized PTM websites that will produce explicit ailments if prevented. Our outcomes present proof of a considerable affect of PTM-specific removing on the pathogenesis of genetic ailments and phenotypes.
Human Codon Utilization: The Genetic Foundation of Pathogen Latency
Infectious ailments pose two important compelling points. First, the identification of the molecular elements that enable continual infections, that’s, the customarily fully asymptomatic coexistence of infectious brokers with the human host. Second, the definition of the mechanisms that enable the swap from pathogen dormancy to pathologic (re)activation.
Furthering earlier research, the current examine (1) analyzed the frequency of prevalence of synonymous codons in coding DNA, that’s, codon utilization, as a genetic device that guidelines protein expression; (2) described how human codon utilization can inhibit protein expression of infectious brokers throughout latency, in order that pathogen genes the codon utilization of which doesn’t conform to the human codon utilization can’t be translated; and (3) framed human codon utilization among the many front-line devices of the innate immunity towards infections.
In parallel, it was proven that, whereas genetics can account for the molecular foundation of pathogen latency, the modifications of the quantitative relationship between codon frequencies and isoaccepting tRNAs throughout cell proliferation supply a biochemical mechanism that explains the pathogen switching to (re)activation. Immunologically, this examine warns that utilizing codon optimization methodologies can (re)activate, potentiate, and immortalize in any other case quiescent, asymptomatic pathogens, thus resulting in uncontrollable pandemics.
Engineered human induced pluripotent cells allow genetic code enlargement in mind organoids
Human induced pluripotent stem cell (hiPSC) expertise has revolutionized human biology. A variety of cell varieties and tissue fashions will be derived from hiPSCs to review advanced human ailments. Right here, we use PiggyBac mediated transgenesis to engineer hiPSCs with an expanded genetic code. We reveal that genomic integration of expression cassettes for a pyrrolysyl-tRNA synthetase (PylRS), pyrrolysyl-tRNA (PylT) and the goal protein of curiosity permits site-specific incorporation of a non-canonical amino acid (ncAA) in response to amber cease codons.
West Nile Virus Envelope Peptide |
|||
| MBS151884-5x005mg | MyBiosource | 5x0.05mg | EUR 770 |
West Nile Virus Envelope Peptide |
|||
| MBS152478-005mg | MyBiosource | 0.05mg | EUR 175 |
West Nile Virus Envelope Peptide |
|||
| MBS152478-5x005mg | MyBiosource | 5x0.05mg | EUR 770 |
West Nile Virus Envelope Peptide |
|||
| MBS152970-005mg | MyBiosource | 0.05mg | EUR 175 |
West Nile Virus Envelope Peptide |
|||
| MBS152970-5x005mg | MyBiosource | 5x0.05mg | EUR 770 |
West Nile virus envelope protein |
|||
| MBS596182-1mg | MyBiosource | 1mg | EUR 425 |
West Nile virus envelope protein |
|||
| MBS596182-2mg | MyBiosource | 2mg | EUR 700 |
West Nile virus envelope protein |
|||
| MBS596182-5mg | MyBiosource | 5mg | EUR 1505 |
West Nile Virus Envelope Protein |
|||
| REC31614-100 | The Native Antigen Company | 0.1 | EUR 536.91 |
|
Description: Recombinant West Nile Virus Envelope protein produced in HEK293 human cells. Product contains a C-terminal His-tag. |
|||
West Nile Virus Envelope Protein |
|||
| REC31614-500 | The Native Antigen Company | 0.5 | EUR 2053.66 |
|
Description: Recombinant West Nile Virus Envelope protein produced in HEK293 human cells. Product contains a C-terminal His-tag. |
|||
West Nile Virus Envelope Antibody |
|||
| 3437-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
|||
West Nile Virus Envelope Antibody |
|||
| 3437-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
|||
West Nile Virus Envelope Antibody |
|||
| 3439-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
|||
West Nile Virus Envelope Antibody |
|||
| 3439-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
|||
West Nile Virus Envelope Antibody |
|||
| 3441-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
|||
West Nile Virus Envelope Antibody |
|||
| 3441-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
|||
West Nile Virus Envelope Antibody |
|||
| 24282 | SAB | 100ul | EUR 479 |
West Nile Virus Envelope Antibody |
|||
| 24282-100ul | SAB | 100ul | EUR 468 |
West Nile Virus Envelope Antibody |
|||
| 24283 | SAB | 100ul | EUR 479 |
West Nile Virus Envelope Antibody |
|||
| 24283-100ul | SAB | 100ul | EUR 468 |
West Nile Virus Envelope Antibody |
|||
| 24284 | SAB | 100ul | EUR 479 |
West Nile Virus Envelope Antibody |
|||
| 24284-100ul | SAB | 100ul | EUR 468 |
West Nile Virus Envelope Antibody |
|||
| MBS150323-01mg | MyBiosource | 0.1mg | EUR 445 |
West Nile Virus Envelope Antibody |
|||
| MBS150323-5x01mg | MyBiosource | 5x0.1mg | EUR 1965 |
West Nile Virus Envelope Antibody |
|||
| MBS150612-01mg | MyBiosource | 0.1mg | EUR 445 |
West Nile Virus Envelope Antibody |
|||
| MBS150612-5x01mg | MyBiosource | 5x0.1mg | EUR 1965 |
West Nile Virus Envelope Antibody |
|||
| MBS150867-01mg | MyBiosource | 0.1mg | EUR 445 |
West Nile Virus Envelope Antibody |
|||
| MBS150867-5x01mg | MyBiosource | 5x0.1mg | EUR 1965 |
West Nile Virus Envelope Antibody |
|||
| MBS9402248-01mL | MyBiosource | 0.1mL | EUR 495 |
West Nile Virus Envelope Antibody |
|||
| MBS9402248-5x01mL | MyBiosource | 5x0.1mL | EUR 2075 |
West Nile Virus Envelope Antibody |
|||
| MBS9404327-01mL | MyBiosource | 0.1mL | EUR 495 |
West Nile Virus Envelope Antibody |
|||
| MBS9404327-5x01mL | MyBiosource | 5x0.1mL | EUR 2075 |
West Nile Virus Envelope Antibody |
|||
| MBS9414904-01mL | MyBiosource | 0.1mL | EUR 495 |
West Nile Virus Envelope Antibody |
|||
| MBS9414904-5x01mL | MyBiosource | 5x0.1mL | EUR 2075 |
West Nile Virus Envelope Recombinant |
|||
| rAP-5504 | Angio Proteomie | Inquiry | Ask for price |
West Nile Virus, Envelope Protein (PE) |
|||
| MBS6125982-01mL | MyBiosource | 0.1(mL | EUR 1480 |
West Nile Virus, Envelope Protein (PE) |
|||
| MBS6125982-5x01mL | MyBiosource | 5x0.1mL | EUR 6505 |
West Nile Virus, Envelope Protein (PE) |
|||
| MBS6125983-01mL | MyBiosource | 0.1(mL | EUR 840 |
West Nile Virus, Envelope Protein (PE) |
|||
| MBS6125983-5x01mL | MyBiosource | 5x0.1mL | EUR 3640 |
West Nile Virus, Envelope Protein (AP) |
|||
| MBS6124813-01mL | MyBiosource | 0.1(mL | EUR 1480 |
West Nile Virus, Envelope Protein (AP) |
|||
| MBS6124813-5x01mL | MyBiosource | 5x0.1mL | EUR 6505 |
West Nile Virus, Envelope Protein (AP) |
|||
| MBS6124814-01mL | MyBiosource | 0.1(mL | EUR 840 |
West Nile Virus, Envelope Protein (AP) |
|||
| MBS6124814-5x01mL | MyBiosource | 5x0.1mL | EUR 3640 |
West Nile Virus, Envelope Protein (HRP) |
|||
| MBS6125748-01mL | MyBiosource | 0.1(mL | EUR 1480 |
West Nile Virus, Envelope Protein (HRP) |
|||
| MBS6125748-5x01mL | MyBiosource | 5x0.1mL | EUR 6505 |
West Nile Virus, Envelope Protein (HRP) |
|||
| MBS6125749-01mL | MyBiosource | 0.1(mL | EUR 840 |
West Nile Virus, Envelope Protein (HRP) |
|||
| MBS6125749-5x01mL | MyBiosource | 5x0.1mL | EUR 3640 |
West Nile Virus, Envelope Protein (APC) |
|||
| MBS6125047-01mL | MyBiosource | 0.1(mL | EUR 1480 |
West Nile Virus, Envelope Protein (APC) |
|||
| MBS6125047-5x01mL | MyBiosource | 5x0.1mL | EUR 6505 |
West Nile Virus, Envelope Protein (APC) |
|||
| MBS6125048-01mL | MyBiosource | 0.1(mL | EUR 840 |
West Nile Virus, Envelope Protein (APC) |
|||
| MBS6125048-5x01mL | MyBiosource | 5x0.1mL | EUR 3640 |
West Nile Virus, Envelope Protein (FITC) |
|||
| MBS6125515-01mL | MyBiosource | 0.1(mL | EUR 1480 |
West Nile Virus, Envelope Protein (FITC) |
|||
| MBS6125515-5x01mL | MyBiosource | 5x0.1mL | EUR 6505 |
West Nile Virus, Envelope Protein (FITC) |
|||
| MBS6125516-01mL | MyBiosource | 0.1(mL | EUR 840 |
West Nile Virus, Envelope Protein (FITC) |
|||
| MBS6125516-5x01mL | MyBiosource | 5x0.1mL | EUR 3640 |
West Nile Envelope Virus Protein |
|||
| abx260322-10g | Abbexa | 10 µg | EUR 950 |
West Nile Envelope Virus Protein |
|||
| 20-abx260322 | Abbexa |
|
|
West Nile Envelope Virus Protein |
|||
| abx260322-2g | Abbexa | 2 µg | EUR 350 |
West Nile Virus, Envelope Protein (Biotin) |
|||
| MBS6125281-01mL | MyBiosource | 0.1(mL | EUR 1480 |
West Nile Virus, Envelope Protein (Biotin) |
|||
| MBS6125281-5x01mL | MyBiosource | 5x0.1mL | EUR 6505 |
West Nile Virus, Envelope Protein (Biotin) |
|||
| MBS6125282-01mL | MyBiosource | 0.1(mL | EUR 840 |
West Nile Virus, Envelope Protein (Biotin) |
|||
| MBS6125282-5x01mL | MyBiosource | 5x0.1mL | EUR 3640 |
West Nile Virus, Envelope, Recombinant (WNV) |
|||
| MBS637537-01mg | MyBiosource | 0.1mg | EUR 475 |
West Nile Virus, Envelope, Recombinant (WNV) |
|||
| MBS637537-05mg | MyBiosource | 0.5mg | EUR 1000 |
West Nile Virus, Envelope, Recombinant (WNV) |
|||
| MBS637537-5x05mg | MyBiosource | 5x0.5mg | EUR 4345 |
West Nile Virus, Envelope, Recombinant (WNV) |
|||
| MBS636618-01mg | MyBiosource | 0.1mg | EUR 715 |
West Nile Virus, Envelope, Recombinant (WNV) |
|||
| MBS636618-5x01mg | MyBiosource | 5x0.1mg | EUR 2990 |
West Nile Virus Envelope Protein Antibody |
|||
| abx022312-1mg | Abbexa | 1 mg | EUR 1296 |
West Nile Virus Envelope Protein Antibody |
|||
| abx022312-400l | Abbexa | 400 µl | Ask for price |
West Nile Virus Envelope Protein Antibody |
|||
| abx022312-80l | Abbexa | 80 µl | EUR 1250 |
West Nile Virus Envelope Protein Antibody |
|||
| abx022314-1mg | Abbexa | 1 mg | EUR 1228.8 |
West Nile Virus Envelope Protein Antibody |
|||
| abx022314-400l | Abbexa | 400 µl | Ask for price |
West Nile Virus Envelope Protein Antibody |
|||
| abx022314-80l | Abbexa | 80 µl | EUR 1362.5 |
West Nile Virus Envelope Protein Antibody |
|||
| abx022315-1mg | Abbexa | 1 mg | EUR 1296 |
West Nile Virus Envelope Protein Antibody |
|||
| abx022315-400l | Abbexa | 400 µl | Ask for price |
West Nile Virus Envelope Protein Antibody |
|||
| abx022315-80l | Abbexa | 80 µl | EUR 1250 |
West Nile Virus Envelope Protein Antibody |
|||
| abx022316-1mg | Abbexa | 1 mg | EUR 1296 |
West Nile Virus Envelope Protein Antibody |
|||
| abx022316-400l | Abbexa | 400 µl | Ask for price |
West Nile Virus Envelope Protein Antibody |
|||
| abx022316-80l | Abbexa | 80 µl | EUR 1250 |
Recombinant West Nile Envelope Virus |
|||
| 7-07960 | CHI Scientific | 100µg | Ask for price |
Recombinant West Nile Envelope Virus |
|||
| 7-07961 | CHI Scientific | 500µg | Ask for price |
Recombinant West Nile Envelope Virus |
|||
| 7-07962 | CHI Scientific | 1000µg | Ask for price |
West Nile Envelope Virus (Recombinant) |
|||
| 22060756-1 | Bio-WORLD | 100 µg | EUR 344.89 |
West Nile Virus, Envelope (West Nile Virus E Protein, WNV Envelope Protein, Envelope Protein, Genome Polyprotein, Major Envelope Protein E, WNVgp1) |
|||
| MBS628104-01mg | MyBiosource | 0.1mg | EUR 650 |
West Nile Virus, Envelope (West Nile Virus E Protein, WNV Envelope Protein, Envelope Protein, Genome Polyprotein, Major Envelope Protein E, WNVgp1) |
|||
| MBS628104-5x01mg | MyBiosource | 5x0.1mg | EUR 2765 |
West Nile Virus Envelope Recombinant Protein |
|||
| 53-361 | ProSci | 0.01 mg | EUR 714.3 |
|
Description: West Nile Virus Envelope Recombinant Protein |
|||
West Nile Virus Envelope recombinant antigen |
|||
| 00401-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: West Nile Virus Envelope recombinant antigen-Immunodominant region |
|||
West Nile Virus Envelope recombinant antigen |
|||
| 00401-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: West Nile Virus Envelope recombinant antigen-Immunodominant region |
|||
Polyclonal West Nile Virus Envelope Antibody |
|||
| AMM05448G | Leading Biology | 0.1 mg | EUR 790.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human West Nile Virus Envelope . This antibody is tested and proven to work in the following applications: |
|||
Polyclonal West Nile Virus Envelope Antibody |
|||
| AMM05449G | Leading Biology | 0.1 mg | EUR 790.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human West Nile Virus Envelope . This antibody is tested and proven to work in the following applications: |
|||
Polyclonal West Nile Virus Envelope Antibody |
|||
| APR11226G | Leading Biology | 0.1 mg | EUR 790.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human West Nile Virus Envelope . This antibody is tested and proven to work in the following applications: |
|||
West Nile Virus Envelope recombinant antigen |
|||
| MBS485131-01mg | MyBiosource | 0.1mg | EUR 300 |
West Nile Virus Envelope recombinant antigen |
|||
| MBS485131-1mg | MyBiosource | 1mg | EUR 1300 |
West Nile Virus Envelope recombinant antigen |
|||
| MBS485131-5x1mg | MyBiosource | 5x1mg | EUR 5795 |
Recombinant West Nile Virus Envelope Protein |
|||
| P1065-10 | Biovision | each | EUR 189.6 |
Recombinant West Nile Virus Envelope Protein |
|||
| P1065-50 | Biovision | each | EUR 366 |
West Nile Virus Envelope (WNV E) Antibody |
|||
| abx201395-100l | Abbexa | 100 µl | EUR 450 |
West Nile Virus Envelope (WNV E) Antibody |
|||
| abx201395-50l | Abbexa | 50 µl | EUR 312.5 |
West Nile Virus Envelope (WNV E) Antibody |
|||
| abx201396-100l | Abbexa | 100 µl | EUR 450 |
West Nile Virus Envelope (WNV E) Antibody |
|||
| abx201396-50l | Abbexa | 50 µl | EUR 312.5 |
West Nile Virus Envelope Protein ELISA Kit |
|||
| VPK-5154 | Cell Biolabs | 96 assays | EUR 548 |
|
Description: Excepted Quantities |
|||
West Nile Virus, Envelope Protein (MaxLight 405) |
|||
| MBS6193924-01mL | MyBiosource | 0.1(mL | EUR 1480 |
West Nile Virus, Envelope Protein (MaxLight 405) |
|||
| MBS6193924-5x01mL | MyBiosource | 5x0.1mL | EUR 6505 |
West Nile Virus, Envelope Protein (MaxLight 405) |
|||
| MBS6193925-01mL | MyBiosource | 0.1(mL | EUR 840 |
West Nile Virus, Envelope Protein (MaxLight 405) |
|||
| MBS6193925-5x01mL | MyBiosource | 5x0.1mL | EUR 3640 |
West Nile Virus, Envelope Protein (MaxLight 650) |
|||
| MBS6225949-01mL | MyBiosource | 0.1(mL | EUR 1480 |
West Nile Virus, Envelope Protein (MaxLight 650) |
|||
| MBS6225949-5x01mL | MyBiosource | 5x0.1mL | EUR 6505 |
West Nile Virus, Envelope Protein (MaxLight 650) |
|||
| MBS6225950-01mL | MyBiosource | 0.1(mL | EUR 840 |
West Nile Virus, Envelope Protein (MaxLight 650) |
|||
| MBS6225950-5x01mL | MyBiosource | 5x0.1mL | EUR 3640 |
West Nile Virus, Envelope Protein (MaxLight 490) |
|||
| MBS6204599-01mL | MyBiosource | 0.1(mL | EUR 1480 |
West Nile Virus, Envelope Protein (MaxLight 490) |
|||
| MBS6204599-5x01mL | MyBiosource | 5x0.1mL | EUR 6505 |
West Nile Virus, Envelope Protein (MaxLight 490) |
|||
| MBS6204600-01mL | MyBiosource | 0.1(mL | EUR 840 |
West Nile Virus, Envelope Protein (MaxLight 490) |
|||
| MBS6204600-5x01mL | MyBiosource | 5x0.1mL | EUR 3640 |
West Nile Virus, Envelope Protein (MaxLight 550) |
|||
| MBS6215274-01mL | MyBiosource | 0.1(mL | EUR 1480 |
West Nile Virus, Envelope Protein (MaxLight 550) |
|||
| MBS6215274-5x01mL | MyBiosource | 5x0.1mL | EUR 6505 |
West Nile Virus, Envelope Protein (MaxLight 550) |
|||
| MBS6215275-01mL | MyBiosource | 0.1(mL | EUR 840 |
West Nile Virus, Envelope Protein (MaxLight 550) |
|||
| MBS6215275-5x01mL | MyBiosource | 5x0.1mL | EUR 3640 |
West Nile Virus, Envelope Protein (MaxLight 750) |
|||
| MBS6236624-01mL | MyBiosource | 0.1(mL | EUR 1480 |
West Nile Virus, Envelope Protein (MaxLight 750) |
|||
| MBS6236624-5x01mL | MyBiosource | 5x0.1mL | EUR 6505 |
West Nile Virus, Envelope Protein (MaxLight 750) |
|||
| MBS6236625-01mL | MyBiosource | 0.1(mL | EUR 840 |
West Nile Virus, Envelope Protein (MaxLight 750) |
|||
| MBS6236625-5x01mL | MyBiosource | 5x0.1mL | EUR 3640 |
West Nile Virus EnvelopeHis |
|||
| PR-1275 | Jena Bioscience GmbH | 100µg | EUR 292.28 |
|
Description: recombinant, E. coli |
|||
OPNB00039-100UG - West Nile Virus - Envelope protein |
|||
| OPNB00039-100UG | Aviva Systems Biology | 100ug | EUR 658 |
OPNB00039-500UG - West Nile Virus - Envelope protein |
|||
| OPNB00039-500UG | Aviva Systems Biology | 500ug | EUR 2656 |
West Nile Virus Envelope Domain III (WNV ED3) Antibody |
|||
| abx201397-100l | Abbexa | 100 µl | EUR 450 |
West Nile Virus Envelope Domain III (WNV ED3) Antibody |
|||
| abx201397-50l | Abbexa | 50 µl | EUR 312.5 |
West Nile Virus Envelope Domain III (WNV ED3) Antibody |
|||
| abx201398-100l | Abbexa | 100 µl | EUR 450 |
West Nile Virus Envelope Domain III (WNV ED3) Antibody |
|||
| abx201398-50l | Abbexa | 50 µl | EUR 312.5 |
West Nile Virus Envelope Domain III (WNV ED3) Antibody |
|||
| abx201399-100l | Abbexa | 100 µl | EUR 450 |
West Nile Virus Envelope Domain III (WNV ED3) Antibody |
|||
| abx201399-50l | Abbexa | 50 µl | EUR 312.5 |
OAGA07998-100UL - West Nile virus Envelope protein Antibody |
|||
| OAGA07998-100UL | Aviva Systems Biology | 100ul | EUR 369 |
OAGA08675-100UL - West Nile virus Envelope protein Antibody |
|||
| OAGA08675-100UL | Aviva Systems Biology | 100ul | EUR 369 |
West Nile Virus Envelope Recombinant Protein 6-his liquid |
|||
| IWNVWNVENVR6HIS10UG | Innovative research | each | EUR 851 |
|
Description: West Nile Virus Envelope Recombinant Protein 6-his liquid |
|||
Neural stem cells, neurons and mind organoids derived from the engineered hiPSCs proceed to precise the amber suppression equipment and produce ncAA-bearing reporter. The integrated ncAA can function a minimal bioorthogonal deal with for additional modifications by labeling with fluorescent dyes. Website-directed ncAA mutagenesis will open a variety of functions to probe and manipulate proteins in mind organoids and different hiPSC-derived cell varieties and complicated tissue fashions.
